Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title A multicenter, phase 3, randomized, open-label, active-controlled, parallel-group trial investigating the safety, tolerability, and efficacy of TransCon hGH administered once a week versus standard daily hGH replacement therapy over 52 weeks in prepubertal children with growth hormone deficiency (GHD) (TransCon hGH CT-301)
Description A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Study visits will be in downtown Buffalo, Amherst or Hamburg
Objective A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily.
Principal Investigator QUATTRIN, TERESA
Age Group Children
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT02781727/
Status Open
Key Eligibility Boys: 3-12 years
Girls: 3-11 years
Growth Hormone Deficiency
Disease Group Children's Health/Pediatrics; Endocrine Diseases
Treatment TransCon hGH
standard human growth hormone (hGH) replacement therapy
Contact TEJAL SHELAT
716-829-3141
tshelat@upa.chob.edu